Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Inclusion Criteria: * Patients must have small cell lung cancer confirmed by the Department of Pathology at Memorial Sloan-Kettering Cancer Center. * Patients may have limited or extensive stage disease at the time of diagnosis. * Patients must have completed first-line therapy, with or without thoracic and/or cranial irradiation, and have achieved either a complete response or partial response to therapy without subsequent evidence of disease progression. * At least 3 weeks must have elapsed between the time the patient completed chemotherapy and the first vaccination. * No more than 8 weeks can elapse between the time the patient completed chemotherapy and the first vaccination. * If the patient received thoracic or cranial irradiation after completing the chemotherapy, at least 1 week must have elapsed after the radiation before the first vaccination. Patients must have recovered from the acute toxicities of the radiation prior to starting the vaccine therapy. * Karnofsky Performance Status \> or = to 70%. * Hematologic parameters: * WBC \> or = to 3.0 x 10\^3 cells/µl * Total lymphocyte count \> or = to 0.5 x 10\^3 cells/µl * Platelet count \> 100,000/µl * Biochemical parameters * Creatinine clearance \> or = to 40 ml/min * Total bilirubin \< or = to 1.5 x upper limits of normal * AST and ALT \< or = to 2.5 x upper limits of normal * Patients must be able to give written informed consent. * Patients must be ≥ 18 years old. Exclusion Criteria: * Patients with progression of disease after first-line chemotherapy. * Pregnant or lactating women. * Patients with a history of immunodeficiency or autoimmune disease, or who have undergone radiation to the spleen or splenectomy. * Patients with a history of leptomeningeal disease. * Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments. * Patients with serious unstable medical illness. * Patients taking systemic corticosteroids. * Patients with peripheral sensory neuropathy \> grade 1. * Patients who have used non-steroidal anti-inflammatory medications within 2 weeks of vaccination.